AstraZeneca, Daiichi hit first goal in pivotal breast cancer ADC trial
AstraZeneca and Daiichi Sankyo are coming for Gilead Sciences' breast cancer business. The partners plan to file for approval of datopotamab deruxtecan (Dato-DXd) after linking their antibody-drug conjugate (ADC) to improved outcomes, although the immature overall survival (OS) data leave a key question unanswered.
